Welcome & Introduction
Charles Papp, M.D. President, Lexington Medical Society Lexington Medical Society
Opioid Symposium: Perspectives, Connections, & Strategies for Action October 16, 2019
Welcome & Introduction Charles Papp, M.D. President, - - PowerPoint PPT Presentation
Lexington Medical Society Opioid Symposium: Perspectives, Connections, & Strategies for Action October 16, 2019 Welcome & Introduction Charles Papp, M.D. President, Lexington Medical Society LMS Opioid Symposium Thank you to our
Charles Papp, M.D. President, Lexington Medical Society Lexington Medical Society
Opioid Symposium: Perspectives, Connections, & Strategies for Action October 16, 2019
LMS Opioid Symposium
Lexington Medical Society
Opioid Symposium: Perspectives, Connections, & Strategies for Action
The opioid crisis has grown to the point where it penetrates all walks of life, all occupations, and is found in every
physicians with tools and resources they can use in their practices. Objectives: ▪ Inform physicians & community leaders on: ▪ The background & scope of the opioid crisis in Lexington ▪ Perspectives from organizations on the front lines of the crisis ▪ Identify ways physicians and community leaders can connect patients and community members to support
LMS Opioid Symposium
LMS Opioid Symposium
For CME credit:
LMS Opioid Symposium
Charles Papp, M.D.
President, LMS
Andrea James
Community Response Strategist for Mayor Linda Gorton
Tuyen Tran, M.D., MBA
LMS Executive Board Chair Owner and CEO, 2nd Chance
Danesh Mazloomdoost, M.D.
Medical Director, Wellward Regenerative Medicine
Chad Traylor
Battalion Chief, EMS
Ryan Stanton, M.D.
Emergency Medicine physician with Central Emergency Physicians at Baptist Health Lexington & Chief Medical contributor for WKYT TV
Kraig Humbaugh, M.D., MPH
Commissioner of Health Lexington-Fayette County Health Department
Lou Anna Red Corn
Fayette Commonwealth’s Attorney
Michelle Lofwall, M.D., DFASAM
Professor of Behavioral Science & Psychiatry and Bell Alcohol & Addictions Chair at U.K. Center on Drug & Alcohol Research.
Mark Jorrisch, M.D., DFASAM
Immediate Past President Kentucky Society of Addiction Medicine
Catherine Hines
SUD Education and Outreach Coordinator Findhelpnowky.org
Podium
LMS Opioid Symposium
5
4 3 2 1
Sponsors Dinner Buffet P A N E L Community Resources
1. Health Department 2. Chrysalis House 3. Find Help Now KY.org 4. KORE (KY Opioid Response Effort) 5. Additional literature
LMS Opioid Symposium
▪ Please save your questions for the panel at the end ▪ We have distributed question cards at each table ▪ Make sure you have signed in and complete the survey in order to receive the CME credit
Andrea James Special Projects Coordinator, Mayor’s Office LMS Opioid Symposium
Andrea James serves as Community Response Strategist for Mayor Linda
First District and has the distinct honor of being the first black woman to serve as an elected city council member in Lexington. Andrea has worked in local government, philanthropy and various medical administrative roles. Outside of her work with Mayor Gorton, she is co-owner of S & A Strategies, a consulting firm specializing in intentional inclusion and equity.
Melissa Combs LMS Opioid Symposium
Tuyen Tran, M.D., MBA LMS Opioid Symposium
Tuyen Tran, M.D. emigrated from South Vietnam after the war. He completed his undergraduate in biology/chemistry and medical school at the University of Missouri – Kansas City in a six-year
addiction medicine.
Tuyen T. Tran, MD, MBA
pain
imaging studies and antibiotics!!
patients
– Leftover pills are the problem
– Dr. David Proctor, the “Godfather of Pill Mills” – 1992-2001, America’s first “pill mill” in South Shore, KY
– Too many patients are suffering unnecessarily because of inadequate pain management – Physicians needed education to dispel the concern for addiction – Insurances were not reimbursing for non-pharmacologic modalities for the treatment of chronic pain
– Retrospective review of 11,882 hospitalized patients who received narcotics – Four patients were found to have “well documented addiction”
– Iatrogenic risk was low in 38 chronic non-cancer pain patients treated with
promoted “Pain is the Fifth Vital Sign”
Organizations) embraced the “Pain is the Fifth Vital Sign”
treatment of pain, especially with opioids
– Inferred sanctions if pain was inadequately controlled
– Collection of patient data was necessary for improvement – Distinction between patient satisfaction and quality of care BLURRED
the value-based purchasing program
– Patient experience collected via HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) – “Did hospital staff do everything they could to help you with your pain?”
bonuses)
– CMS only required 300 surveys in a 12-month period – Only a small number of patients actually completed the surveys – A single poor survey could significantly impact whether the hospital achieved the required 90% percentile goal of patient satisfaction – Thus, every patient must be satisfied!
physicians were often compelled to satisfy the patients, despite their reservations about the need for opioids
among the 50 states
– Largest demographic: 35-44 y/o – Heroin: 22% of OD (DOWN from 34% in 2016) – Fentanyl: 52% of OD (UP from 47% in 2016)
Campbell, and Kenton
Breathitt, and Scott
– 782 died in traffic accidents – 263 people were murdered
– CDC: KY had 3rd highest rate of opioid use at delivery among the 50 states
– 2000: 30% – 2009: 38%
2012 to 2016
– 2012: 1,525 – 2016: 1,916 (25% increase)
– 2012: 911 – 2016: 1836
$82M
– Strong link between RISING opioid prescriptions and DECLINING workforce participation rates (percentage of people employed or looking for work) – Half of men aged 25-54 who are not in the workforce take pain medication daily
– Workforce participation rate was 4.6% LESS on average in counties with high rates of opioid prescribing
– Kentucky had one of the lowest workforce participation rates in the country – Contributing factors:
– Reduce number of offenders going to jail for drug possession – Remove barriers to people in recovery from acquiring employment
Danesh Mazloomdoost, M.D. LMS Opioid Symposium
Danesh Mazloomdoost, MD is a Johns Hopkins & MD Anderson trained anesthesiologist, pain, and regenerative specialist. As an international speaker, author, and advocate for reform in pain management, Dr. Danesh consults with private and governmental organizations to develop protocols for pain that minimize opioid dependency, improve patient satisfaction and health outcomes. His new book, Fifty Shades of Pain: How to Cheat on your Surgeon with a Drugfree Affair has become an Amazon international best- seller in ten categories. He is now the Medical Director of Wellward Regenerative Medicine in Lexington Kentucky, the flagship for a new and sustainable approach to managing pain while avoiding drugs or surgery.
Battalion Chief Chad Traylor LMS Opioid Symposium
Joined the Lexington Fire Department in 2003. Began career assigned to a fire engine and after completing paramedic training transferred to an ambulance. Throughout the years has held the assignments of a Company Officer, Hazardous Material Team Leader, District Major, Special Operations Commander and is currently the EMS Battalion Chief.
Ryan Stanton, M.D. LMS Opioid Symposium
EM doc with Central Emergency Physicians at Baptist Health Lexington. Chief Medical contributor for WKYT TV and producer of “The Doc Is In”, the weekly heath segment airing in 6 TV markets throughout the
physician for the AMR/NASCAR Safety Team. National Spokesperson for the American College of Emergency Physicians and producer of the ACEP Frontline Podcast. Dr. Stanton has been speaking around the country regarding opioids for the past 10+ years and is currently involved with the KHA SOS initiative.
Kraig Humbaugh, M.D. LMS Opioid Symposium
As Commissioner of Health, Kraig E. Humbaugh, MD, MPH is the chief executive officer and medical director for the Lexington-Fayette County Health Department. He is a board-certified pediatrician who has practiced medicine for over twenty-five years in community, academic and public health settings. Dr. Humbaugh earned his undergraduate degree from Vanderbilt University, studied as a Fulbright Scholar at the University of Otago in New Zealand, and received his medical degree from Yale University. He holds a Master of Public Health degree from Johns Hopkins University.
Lexington Medical Society’s Opioid Symposium October 16, 2019
Kraig E. Humbaugh, MD, MPH Commissioner, Lexington-Fayette County Health Department kraig.humbaugh@ky.gov
35
▪ Provides new, sterile needles and syringes ▪ Provides safe disposal site for contaminated needles and syringes
Fridays 11 AM-4 PM
Pike
needle exchange
department
Compare to lifetime cost of one new case of HIV (>$350,000)or cost of treating one case of hepatitis C ($30,000-$50,000)
September 4, 2015 – September 6, 2019
37
82% 42% 39% 24% 43% 39% 39% 21% 25% 17% 31% 38% 34% 32% 28% 21% 24% 23% 23% 21% 19% 15% 13% 14% 14% 13% 16% 16% 13% 15% 13% 15% 11% 13% 12%9% 8% 9%12%9%10% 10%8% 8% 7%10%7% 7% 18% 58% 61% 76% 57% 61% 61% 79% 75% 83% 69% 62% 66% 68% 72% 79% 76% 77% 77% 79% 81% 85% 87% 86% 86% 87% 84% 84% 87% 85% 87% 85% 89% 87% 88% 91% 92% 91% 88% 91% 90% 90% 92% 92% 93% 90% 93% 93% 200 400 600 800 1000 1200 1400 Sep '15 Oct Nov Dec Jan '16 Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan '17 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan '18 Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan '19 Feb Mar Apr May Jun July Aug First Visit Repeat Visit
September 4, 2015 – September 6, 2019
38
September 4, 2015 – September 6, 2019
73% 21% 2% 2% 2%
Heroin Methamphetamine Suboxone Oxycodone Cocaine
SELF-REPORTED FIRST TIME CLIENT PARTICIPATION IN TREATMENT/RECOVERY PROGRAMS
March 3, 2018 – September 6, 2019
PAST PARTICIPATION IN A TREATMENT/RECOVERY PROGRAM (n =1515) NUMBER OF TIMES IN TREATMENT/RECOVERY PROGRAM (n=988)
41
Total Number of Needles Received September 4, 2015-September 6, 2019 Total Number of Needles Distributed September 4, 2015-September 6, 2019 943,506 1,152,346 Ratio of needles received to needles distributed: 0.82 : 1
LFUCG, New Vista, Chrysalis House)- over 200
43
been distributed for use in the community setting.
takes about 15-20 minutes total.
and to call emergency medical services
planned.
encourage people to carry and use naloxone when needed.
Commissioner of Health Lexington-Fayette County Health Department
kraig.humbaugh@ky.gov
Lou Anna Red Corn Fayette Commonwealth’s Attorney LMS Opioid Symposium
Lou Anna Red Corn was appointed Fayette Commonwealth’s Attorney in 2016, and elected to the position in 2018. She has been a prosecutor in the office since 1987. Lou Anna serves the state’s prosecutors as treasurer and Best Practice Committee Co-Chair of the Commonwealth Attorney’s Association, she is the current state’s representative to the National District Attorneys Association and the nation’s prosecutor representative on the National Children’s Alliance Board of Directors, the organization that accredits the country’s Children Advocacy Centers.
Michelle Lofwall, M.D. LMS Opioid Symposium
Michelle Lofwall MD is a Professor of Behavioural Science and Psychiatry and the Bell Alcohol and Addictions Chair at the University of Kentucky Center on Drug and Alcohol Research. She is the medical director of the First Bridge
comprehensive care to patients discharging from the emergency room and inpatient medical/surgical services. Her clinical research has been funded by the National Institutes of Health and industry with a focus on OUD. She was as an expert panel member on SAMHSA’s newly published Substance Treatment Improvement Protocol (TIP 63) for Medication Treatment of OUD, a board member of the American Society of Addiction Medicine, an invited speaker to the National Academy of Medicine and recipient of several medical student teaching and mentorship awards.
47 47
48
SUBSTANCE USE RESEARCH AT UK
areas, which grew out of a 2014 Board of Trustees Retreat. These highlight a focus on research where:
pressing; and,
external research support. (see: https://www.research.uky.edu/research-priorities-initiative)
is to prevent and reduce the burden of substance use disorder (SUD) through conducting and translating multidisciplinary and innovative research to inform clinical services, training, public health practice and policy.
49
A partnership with the National Institutes of Health (NIH), the National Institute on Drug Abuse (NIDA), and the Substance Abuse and Mental Health Services Administration (SAMHSA) The funding announcement required specific evidence-based prevention and treatment interventions, including: prevention efforts related to opioid overdose; screening and assessment of
use of medications to treat OUD; and ongoing recovery support
in multiple settings and are required to include healthcare, behavioral health, and justice settings.
THE HEALING COMMUNITIES STUDY
50
The primary aim is to develop an evidence-based integrated strategy to reduce opioid-related overdose deaths by 40% in three years in at least 15 highly affected communities by:
➢ Increasing distribution of naloxone (Narcan) ➢ Increasing the number
individuals receiving medication treatment for opioid use disorder ➢ Increasing retention of people in treatment beyond 6 months ➢ Increasing the number of people receiving recovery support services
THE HEALING COMMUNITIES STUDY
51
THE HEALING COMMUNITIES STUDY
$87 million was awarded to the University of Kentucky (one of four states to receive the award). Massachusetts, New York, and Ohio were also awarded. Our project is being conducted in partnership with numerous federal, state, community, public health, criminal justice, behavioral health, and health care partners. HEALing Communities Study – Kentucky is led by Dr. Sharon Walsh, Director of the UK Center on Drug and Alcohol Research
Massachusetts New York Ohio Kentucky
Rural Urban
53
Design
120 48 35 28 25 19 16
Counties in Kentucky Counties with ≥ 25 opioid overdose deaths per 100,000 residents in 2017 Counties without ‘suppressed data’ (i.e., ≥ 5 opioid
Counties with justice infrastructure (i.e., jails) Counties with treatment infrastructure (i.e., ≥ 1 provider licensed to prescribe medication) Counties with public health infrastructure (i.e., SSP) Counties not already involved in a major UK intervention project
The served area encompasses over 1.8 million people (approximately 41% of the state’s population).
48 counties with > 25 opioid overdose deaths per 100k in 2017
HEALING COMMUNITIES: KENTUCKY
54
Projects were required to target at least 15 counties or cities highly affected by overdose, defined as:
➢ A rate of 25 opioid related overdose deaths per 100,000 persons or higher in the past year ➢ The Kentucky HEALing Communities counties had an average rate of 45.7 opioid-related overdose deaths per 100,000. ➢ Combined total of at least 150 opioid-related overdose fatalities ➢ The Kentucky HEALing Communities counties had a total
764 opioid-related overdose deaths in 2017.
➢ 30% of the counties/cities must be rural
HEALING COMMUNITIES: KENTUCKY
55
Expand access to overdose- reversing naloxone Link people leaving jail and on probation/parole to treatment and naloxone Link clients of harm reduction programs to treatment and naloxone Reduce high-risk prescribing and increase safe disposal of medications Reduce barriers to medication treatment and improve retention in care Provide peer support services to help people through recovery
The project will be guided by local community coalitions and the following potential strategies:
56
➢ Every county in the project will receive a “Care Team” ➢ Communities will be engaged in a communication campaign to reduce stigma and improve awareness of services
Community Coordinator Syringe Service Program Prevention Specialist Treatment Care Navigator Jail Care Navigator Probation and Parole Prevention Specialist Local coalition (ASAP Board)
57
Train-the-trainer overdose education and naloxone training for local health department staff, local pharmacists, and first responders Rigorous evaluation of what works and what does not work could inform intervention rollout for other parts of the state Detailed cost-effectiveness analysis will be shared with policy-makers at the state and local level so that they can consider it in future program funding decisions
Mark Jorrisch, M.D., DFASAM LMS Opioid Symposium
Immediate Past President of KYSAM, distinguished Fellow of ABAM, Board Certified Internal Medicine and Addiction Medicine, practice at BHG Lexington, an OTP offering both methadone and buprenorphine, and at the MORE Center in Louisville, an OTP offering methadone.
No disclosures
(di-acetyl- morphine)
very
lipophilic
rapidly
crosses the blood brain barrier in the Reward Pathway
This is the reason heroin is preferred
morphine by injection
users Withdrawal Normal Euphoria Chronic use Initial use Tolerance & Physical Dependence
Alford DP. http://www.bumc.bu.edu/care/
Ventral
Tegmental Area (VTA)
Nucleus
Accumbens with projections to Prefrontal Cortex
Dopaminer
gic system
Leshner AI. Hosp Pract. 1996
36% 66% 86% 86% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1 to 12 months (n=157; OR=1.0) 1 to 3 years (n=138; OR=3.4) 3 to 5 years (n=59; OR=11.2) 5+ years (n=96; OR=11.2) % Sustaining Abstinence Through Year 8 Duration of Abstinence at Year 7
After 5 years <15% relapse It takes a year of abstinence before <50% relapse
Dennis ML et al. Eval. Rev. 2007
O’Connor PG. JAMA. 2005. Mattick RP, Hall WD. Lancet. 1996. Stimmel B et al. JAMA. 1977.
Alleviate signs/symptoms of physical withdrawal Opioid receptor blockade Diminish and alleviate drug craving Normalize and stabilize perturbed brain neurochemistry
Opioid Antagonist
Naltrexone (full antagonist)
Opioid Agonist
Methadone (full agonist) Buprenorphine (partial agonist)
Mu-opioid receptor antagonist
Not a controlled substance, no special prescribing restrictions
Patients physically dependent must be opioid free for a minimum of 7-10 days before treatment
Also FDA approved for the treatment of alcohol use disorders
Oral naltrexone (generic and brand
Revia)
Well tolerated Duration of action 24-48 hours FDA approved 1984
IM injection extended- release naltrexone (Vivitrol)
IM injection (w/ customized needle)
FDA approved 2010
Good for patients who do not want opioid agonist therapy No risk of diversion (not a controlled substance) No risk of overdose by drug itself Can be administered in any setting (office-based or OTP) Long-acting formulation Treats both opioid use disorder and alcohol use disorder
Difficulty starting—must be fully withdrawn from opioid; > short- acting (6 days); long-acting opioids (7-10 days) Not recommended for pregnant
physically dependent on opioids should receive treatment using methadone or buprenorphine Not suitable for patients with severe liver disease
Loss of tolerance to opioids increases the risk of overdose if relapse occurs
Kampman, K. et al. (2015). The ASAM National Practice Guideline
Oral: 80-90% bioavailability liquid, tablet, and disket formulations
Duration of action
24-36 hours to treat OUD 6-8 hours to treat pain
Proper dosing for OUD
20-40 mg for acute withdrawal > 80 mg for craving, “opioid blockade”
Can be administered parenterally (IV, SQ or IM)
at 80% of the total daily oral dose administered in a divided dose every 12
hours (e.g., 40 mg by mouth every day = 16 mg IV every 12 hours)
Mercadante S. (2013) Handbook of Methadone Prescribing and Buprenorphine Therapy.
Daily nursing assessment Weekly individual and/or group counseling Random supervised drug testing Psychiatric services Medical services Observed daily → “Take
homes” based on stability and time in treatment. Max: 27 take homes. Varies by state, county and individual clinics
Increases overall survival Increases treatment retention Decreases illicit
Decreases hepatitis and HIV seroconversion Decreases criminal activity Increases employment Improves birth
Joseph et al. Mt Sinai J Med. 2000;67:347-364.
Highly regulated: Narcotic Addict Treatment Act 1974 Created methadone clinics (Opioid Treatment Programs) Separate system not involving primary care or pharmacies
Limited access Inconvenient Mixes stable and unstable patients Lack of privacy No ability to “graduate” from program
Stigma: “Methadone is substituting one drug for another…I don’t believe in methadone”
Semi-synthetic analogue of thebaine
Approved by the FDA in 2002 as Schedule III — up to 5 refills
High receptor affinity
Slow dissociation
Ceiling effect for respiratory depression
Partial Mu-
antagonist
Studies (RCT) show buprenorphine (16-24 mg) more effective than placebo and equally effective to moderate doses (80 mg) of methadone on primary outcomes of:
Retention in treatment Abstinence from illicit opioid use Decreased opioid craving Decreased mortality Improved occupational stability Improved psychosocial outcomes
Johnson et al. NEJM 2000; Fudala PJ et al. NEJM 2003; Kakko J et al. Lancet 2003; Sordo L et al. BMJ 2017; Mattick RP et al. Conchrane Syst Rev 2014; Parran TV et al. Drug Alcohol Depend 2010
Psychological support should be
medications for OUD Treatment services should aim to offer onsite, integrated, comprehensive psychosocial support to every patient
While patients should be offered psychosocial support, they should not be denied medication should they refuse such support, but encouragement to utilize psychosocial support should be continued
12 Step Oriented Treatment Self-help Groups Group Therapy Supportive Psychotherapy Cognitive Behavioral Contingency Management Cue Exposure Psychodynamic Network Therapy Community-Based Model Couple or Family Vocational Training Motivational Enhancement Relapse Prevention
76
Treatment Interventions
PCSS Pill counts
Pharmacy collaboration State prescription monitoring reports Urine drug tests Psychosocial & behavioral treatments Appropriate prescribing practices Therapeutic doctor-patient relationship
77
Catherine Hines Coordinator, KY Injury Prevention & Research Center at U.K. LMS Opioid Symposium
Catherine Hines is the Education and Outreach Coordinator for findhelpnowky.org, Kentucky Injury Prevention and Research Center’s treatment locator website. She holds her BA in Classical Studies from Centre
update essential information onto the website as needed. She also reaches
She works with the FindHelpNowKY team in the process of managing interest from other states which may implement this website for their own
researching and making connections with Universities and Colleges throughout the state in an attempt to educate them on the website and its use.
Catherine Hines, SUD Education and Outreach Coordinator
Kentucky Injury Prevention and Research Center Bona fide agent of the Kentucky Department for Public Health University of Kentucky, College of Public Health
A Valuable Tool in the Fight Against Addiction
FindHelpNowKy.org
Project Overview Application in Healthcare Setting Website Demonstration State of Treatment in KY
FindHelpNowKy.org What is it?
Dynamic near-real-time substance use disorder
(SUD) treatment locator and information repository
Valuable tool for healthcare professionals, public
safety officials, and the general public
Unprecedented inter-cabinet collaboration in
response to the opioid and overdose crisis in KY
Resource for research and insights into the state of
SUD treatment in KY
FindHelpNowKy.org Project Overview
Funded for 2016-2019 by Centers for Disease
Control and Prevention (CDC)
National Center for Injury Prevention and Control
Prevention for States (PfS) grant
Funded for 2019-2022 by Centers for Disease
Control and Prevention (CDC)
Overdose Data to Action (OD2A) Grant
Partnerships
Project Team
Terry Bunn, PhD KIPRC Director Dana Quesinberry, JD Principle Investigator Jodie Weber Program Manager Catherine Hines SUD Education and Outreach Coordinator Tyler Jennings Technical and Marketing Coordinator
FindHelpNowKY.org Development Goals
Quick and easy search to facilitate rapid access to
treatment
Near-real-time information on availability of treatment slots Advanced filters to meet specific needs Resource library, including one pagers on SUD topics 1-833-8KY-HELP helpline prominently displayed Dynamic analytics to facilitate research and track state of
treatment in KY
Broad compatibility
FindHelpNowKY.org Development Outputs
Fully designed and tested front- and back-end environments Management interface to track provider engagement 28 one-page documents on variety of SUD topics Informational brochures Pocket cards Instructional videos for public and providers Healthcare provider-patient SUD communication guide
FindHelpNowKY.org Treatment Provider Stats
Currently indexing over 600 KY treatment facilities
Approximately 90% of licensed AODE/BHSO treatment facilities
Over 50 MAT DATA Waivered physicians on board
Approximately 10% of MAT Data Waivered physicians in the state Difficult to reach and engage population
Over 100 data points captured for each facility
From total treatment slots to tobacco use and gender-based bed
assignment policies
Let’s Take a Tour:
FindHelpNowKY.org Application in Healthcare
Massive reduction in time to find available treatment options
Get a list of facilities with openings and sorted by distance in about 20
Quickly find and share resources with patients or their loved ones
Use filters and text search to rapidly narrow list of resources
Match unique patient needs to treatment providers
Filters for demographic info, comorbidity, additional services, payment
methods, etc…
Enhances SBIRT or related processes
Easily fits in to SBIRT intervention and referral steps Healthcare provider communication guide created by KIPRC augments
SBIRT with stages of change model
FindHelpNowKY.org Stats to Date
Since soft launch in Jan 15, 2018: 608 total facilities (~90% of licensed treatment facilities; ~10% of MAT
providers in state)
Over 242,000 unique visitors, 353,000 total visits, 606,000 total pageviews Roughly 50% male, 50% female Over 115,000 searches (41% concerned family, 35% healthcare
professional, 24% individual)
Providers have logged in over 8,000 times to view or update their profiles Currently working on bringing the FindHelpNowKY platform to four
additional states
FindHelpNowKY.org Average Visitor
First time visitor to the site Male Aged 25-44 From Jefferson County or surrounding area Searching on behalf of a friend or family member Looking for residential/inpatient treatment that accepts a form of Medicaid
MAT is a close second
Spends about 6 and a half minutes searching for facilities
FindHelpNowKY.org State of Treatment
Source: Data gathered 06/21/2019 from FindHelpNowKY.org Source: Data gathered 06/21/2019 from FindHelpNowKY.org and Google Analytics
327 190 201 58 93 12 100 200 300 400 OP IOP MAT Detox Reside… Inpatie…
Treatment Options by Treatment Type
Total Facilities
LMS Opioid Symposium
Charles Papp, M.D.
President, LMS
Andrea James
Community Response Strategist for Mayor Linda Gorton
Tuyen Tran, M.D., MBA
LMS Executive Board Chair Owner and CEO, 2nd Chance
Danesh Mazloomdoost, M.D.
Medical Director, Wellward Regenerative Medicine
Chad Traylor
Battalion Chief, EMS
Ryan Stanton, M.D.
Emergency Medicine physician with Central Emergency Physicians at Baptist Health Lexington & Chief Medical contributor for WKYT TV
Kraig Humbaugh, M.D., MPH
Commissioner of Health Lexington-Fayette County Health Department
Lou Anna Red Corn
Fayette Commonwealth’s Attorney
Michelle Lofwall, M.D., DFASAM
Professor of Behavioral Science & Psychiatry and Bell Alcohol & Addictions Chair at U.K. Center on Drug & Alcohol Research.
Mark Jorrisch, M.D., DFASAM
Immediate Past President Kentucky Society of Addiction Medicine
Catherine Hines
SUD Education and Outreach Coordinator Findhelpnowky.org
Podium
Lexington Medical Society
Opioid Symposium: Perspectives, Connections, & Strategies for Action
LMS Opioid Symposium